OPPM
BOLD

Opus Point Partners Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Opus Point Partners Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$487K Hold
17,339
– – 0.88% 28
2019
Q2 		$656K Hold
17,339
– – 0.97% 25
2019
Q1 		$677K Buy
+17,339
New +$497K 0.92% 24

Other funds holding BOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Opus Point Partners Management's BOLD Position: Q3 2019 in Review

Opus Point Partners Management held its Audentes Therapeutics, Inc (BOLD) position steady in Q3 2019 at 17,339 shares worth $487K. The position accounts for 0.88% of the portfolio, ranked #28.

Opus Point Partners Management first reported a position in BOLD in Q1 2019 and has held it in 3 quarters since. The position peaked at $677K in Q1 2019. 149 funds tracked by Wall St. Rank hold BOLD as of Q3 2019.

  • Opus Point Partners Management held 17,339 shares of Audentes Therapeutics, Inc worth $487K as of Q3 2019.
  • Opus Point Partners Management left its Audentes Therapeutics, Inc share count unchanged in Q3 2019.
  • Audentes Therapeutics, Inc made up 0.88% of Opus Point Partners Management's portfolio in Q3 2019, its #28 holding.
  • Opus Point Partners Management first reported a position in Audentes Therapeutics, Inc in Q1 2019 and has held it in 3 quarters since.
  • Opus Point Partners Management's Audentes Therapeutics, Inc position peaked at $677K in Q1 2019.
  • 149 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.